The Challenge of Managing Chronic Wounds
When Quality of Life is a Significant Issue

Pauline Graham-King BSc (Hons) RGN OND
EB Clinical Nurse Specialist-Adults (North) DebRA, Eals Lodge, Tarset, Hexham, Northumberland NE48 1LF

Epidermolysis bullosa

Epidermolysis bullosa is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. There are approximately 5,000 sufferers in the UK and around 500,000 worldwide (equivalent to 1 in 17,000 live births). Patients with recessive dystrophic EB (RDEB) lack the gene that encodes for the protein collagen VII. Without collagen VII, minimal trauma or friction causes the epidermis to separate from the dermis and so blisters form with ease which may then develop into wounds. The internal mucosa is also affected, including the mouth, the oesophagus and corneas. Development of chronic wounds is common as is healing with scarring. Treatment is symptomatic with skin and wound management forming a large part of care.

Wound management in RDEB patients is a complex process and wound care becomes a way of life for affected individuals and their carers. For some patients, symptom control is a more realistic objective than healing. Wounds typically seen in EB range from superficial blister sites that heal with ease which may then develop into wounds. The internal mucosa is also affected, including the mouth, the oesophagus and corneas. Development of chronic wounds is common as is healing with scarring. Treatment is symptomatic with skin and wound management forming a large part of care.

The patient

A 24 year old female patient with severe RDEB suffered head wounds following pediculosis (infestation of head lice). The wounds have gradually become worse over the past 6 years. Many dressings and ointments have been tried, with no improvement. The challenges faced in managing the wounds include, excessive exudate which can leak into the aural canals and eyes causing ear infections, conjunctivitis and blepharitis; infections, in particular Pseudomonas, and possible biofilm formation; extreme sensitivity of the scalp with pain on dressing change; application of a hat or wig which the patient finds very hard to tolerate especially in hot weather.

Treatment with Flaminal®

Although there is no data on the use of Flaminal® in EB patients, existing data supports the use of Flaminal® in heavily exuding wounds and in wounds at high risk of infection. Further, studies have shown that dressing-associated pain may be reduced with Flaminal®. With the patient’s full agreement, it was decided to change the plan of care to using Flaminal® as the primary dressing. Flaminal® Hydro was applied as a thick layer with extreme care using a soft swab and then very carefully smeared onto the scalp wounds. Mepitel and Mepilex Transfer were selected as secondary dressings as Flaminal® did not adhere to them and Actiwrap bandage was used to secure the dressings.

Results

Exudate levels increased initially and the dressing had to be changed on a daily basis for the first five days. As exudate levels decreased, dressing changes were reduced to the patient’s usual regime of every three days. Malodour also decreased. Flaminal® aided debridement and was well tolerated. The application of Flaminal® helped cool the patient’s head and so helped her feel much more comfortable. The wounds did not heal, and are unlikely to heal due to the RDEB, however they had started to granulate around the edges; they were much cleaner and demonstrated no sign of infection. The use of Flaminal® to treat one area of chronic wounds improved the patient’s quality of life so much so that she then applied Flaminal® to chronic wounds on other areas of her body, especially her feet.

Discussion

Wound management of RDEB patients presents a unique challenge. As the barrier function of the skin is severely compromised prevention of infection is a key consideration. In addition, dressing changes may be painful, especially if inappropriate dressings are used. Clinical evidence tends to be limited to case series due to the rarity of the disease. Therefore, good wound care is largely dependent on practitioner’s preference, cost and patient preference.

Flaminal® is an enzyme alginogel with a unique antimicrobial enzymatic complex (glucose oxidase combined with lactoperoxidase, stabilised by guaiacol [GLG]). It is indicated for use on a wide range of wounds where there is the potential for an acquired infection and is available in two formulations depending on exudate levels.

4 weeks after Flaminal® treatment:

RDEB patients in the community are often self-managing, either dressing their own wounds or having a carer dress the wounds, with the decisions ultimately being made by the patient. It is not surprising therefore, that as the patient found a treatment that offered her greater benefits over existing treatments, that she extended the use of Flaminal® to the management of some of her other wounds.

Conclusion

Flaminal® has become a much welcomed addition to the highly limited armamentarium of wound care products suited for the management of chronic wounds in RDEB.

DebRA

Registered Charity No: 1084958.
www.debra.org.uk Telephone No; 01344 771961.
DebRA is a registered charity and provides information, practical help and advice from specialist nurses, social and welfare workers. It is also a means of supporting patients, families and allied healthcare professionals via a website, newsletters and conferences, patient group meetings, home visits and specialist clinics.

Reference List